NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
12/12/2023
Back to search
Official data from USPTO
ADVANTX - PHARMA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Quick snapshot
ADVANTX - PHARMA
ST13
US500000097340255Class
5, 42
Filing
97340255
Registration
7239135
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
19
Latest update
12/12/2023
Classification
Registered
Trademark type
Word
Nice classes
5, 42
Filing date
03/31/2022
Registration date
12/12/2023
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/12/2023
Last transaction
12/12/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Foreign priority
Drawing code
4
Owner type
99
Owner location
Madrid, ES
Examiner
LATTUCA, FRANK
Law office
L90
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
FUNDACION PARA EL DESARROLLO Y LA INNOVACION TECNOLOGICA FUNDITEC
Representatives
Kumiko Ide WENDEROTH, LIND & PONACK, L.L.P.
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical products and preparations for the treatment of neurological disorders and cancer; biological reagents for medical use; pharmaceutical chemical preparations for the treatment of neurological disorders and cancer biopharmaceuticals for the treatment of cancer; pharmaceutical and biological products for the treatment of cancer; pharmaceutical and biological preparations for the treatment of diseases of the central nervous system
Class 42
Scientific research; industrial research in the field of pharmaceutical research and development of drugs and treatments for neurological disorders and cancer; scientific research in biology and chemistry; development of pharmaceutical preparations and drugs; development of pharmaceuticals; Medical and scientific researchconducting clinical trials of pharmaceuticals for others; scientific research in the field of pharmacy; research and development in the pharmaceutical and biotechnology fields; drug discovery services; medical research services; scientific computer programming
Publications
History of USPTO decisions and trademark events.
19 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
12/12/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/26/2023
PUBO
PUBLISHED FOR OPPOSITION
09/26/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/06/2023
FIXD
ELECTRONIC RECORD REVIEW COMPLETE
08/21/2023
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
08/18/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/13/2023
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
08/07/2023
GNSI
INQUIRY TO SUSPENSION E-MAILED
08/07/2023
CNSI
SUSPENSION INQUIRY WRITTEN
08/07/2023
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
08/03/2023
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
07/14/2023
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
01/19/2023
GNSL
LETTER OF SUSPENSION E-MAILED
01/19/2023
CNSL
SUSPENSION LETTER WRITTEN
01/19/2023
DOCK
ASSIGNED TO EXAMINER
01/18/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/05/2022
NWAP
NEW APPLICATION ENTERED
04/04/2022
Continuous trademark protection
Get notified about every new filing that threatens ADVANTX - PHARMA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.